Daily Stock Setups

Beacon Equity Issues Trading Overview for Keryx Biopharmaceuticals

Posted on: Thu, 15 Oct 2009 06:50:00 EDT

Symbols: KG, WPI, PFE, KERX

Are you looking to increase your ETF knowledge?

It is available at: http://www.beaconequity.com/i/KERX

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Keryx Biopharmaceuticals Inc. (KERX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases including renal disease and cancer.

In the report, the analyst notes:

"KERX last month announced that its drug candidate, Zerenex, was well tolerated and safe in a mid-stage study that was testing it specifically for long-term use in patients with end-stage renal disease; this news sending its shares to a new 52-week high. Zerenex is an oral, iron-based compound that attaches itself to phosphates when food is broken down in the stomach to form non-absorbable complexes. The late-stage study for the kidney drug is expected to begin at the end of the year.

"The net income for the second quarter ended June 30, 2009, was $14.1 million, or $0.29 per diluted share, compared to a net loss of $7.7 million, or $0.17 per share, for the second quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $18.0 million in license revenue relating to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii), which eliminated the Company's significant ongoing obligations included in the original agreement, a $1.8 million decrease in research and development expenses related to KRX-0401."

To read the entire report visit: http://www.beaconequity.com/i/KERX

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in the report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Beacon Equity

CONTACT:  Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com

For full details on King Pharmaceuticals Inc (KG) KG. King Pharmaceuticals Inc (KG) has Short Term PowerRatings at TradingMarkets. Details on King Pharmaceuticals Inc (KG) Short Term PowerRatings is available at This Link.

For full details on Watson Pharmaceuticals (WPI) WPI. Watson Pharmaceuticals (WPI) has Short Term PowerRatings at TradingMarkets. Details on Watson Pharmaceuticals (WPI) Short Term PowerRatings is available at This Link.

For full details on Pfizer Inc (PFE) PFE. Pfizer Inc (PFE) has Short Term PowerRatings at TradingMarkets. Details on Pfizer Inc (PFE) Short Term PowerRatings is available at This Link.

For full details on Keryx Biopharmaceuticals (KERX) KERX. Keryx Biopharmaceuticals (KERX) has Short Term PowerRatings at TradingMarkets. Details on Keryx Biopharmaceuticals (KERX) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.